First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge
mBio · 2025
DOI: 10.1128/mbio.01036-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Vincent Dussupt und 29 weiteren Autor:innen. Beteiligte Einrichtung: Viral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Neutralizing, COVID-19, Antibodies, Viral. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of Allergy and Infectious Diseases, U.S. Department of Defense.
Abstract (Originalsprache)
Monoclonal antibodies to SARS-CoV-2 can offer prophylactic and therapeutic protection against severe disease, with particular utility for immunosuppressed and vulnerable populations. With the constant emergence of new variants, understanding the neutralizing potency of monoclonal antibodies to dynamic spike protein epitopes is crucial. We show that a set of VH1-24-derived N-terminal domain (NTD)-directed antibodies, isolated from a convalescent donor early in the pandemic, displayed remarkable neutralization resilience against many Omicron SARS-CoV-2 variants, including BA.2, BA.5, and BQ.1.1. Neutralization potency to these Omicron variants is associated with slower off-rates to the spike protein. Structural characterization of the most potent NTD antibody, WRAIR-2008, revealed a conserved mode of interaction shared with other antibodies of the same multi-donor class. WRAIR-2008 protected mice from weight loss following BA.5 challenge and reduced infectious viral titers in the lungs. Our study highlights the retention of neutralization activity and protection of first-generation VH1-24-derived NTD-directed antibodies to specific Omicron variants and provides valuable insights into the shifting landscape of SARS-CoV-2 variants that are vulnerable to select monoclonal antibodies. IMPORTANCE As SARS-CoV-2 circulating variants evolve, it is important to understand the vulnerabilities of these viruses to neutralizing antibodies. Within this manuscript, we describe first-generation antibodies isolated following infection with WA-1 that retain viral neutralization to subsequent Omicron variants by targeting a site of viral vulnerability called the NTD. This work highlights the shifting landscape of SARS-CoV-2 variants and provides mechanistic insights into how antibodies from prior infections may play a role in preventing subsequent SARS-CoV-2 variant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
- Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
- Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
- Trudeau Institute, Saranac Lake, New York, USA.
ORCID-Profile: Vincent Dussupt, Jaime L Jensen, Tongqing Zhou, Peter D Kwong, Victoria R Polonis, M Gordon Joyce, Shelly J Krebs
Förderung
- NIGMS NIH HHS
- National Institute of Allergy and Infectious Diseases
- U.S. Department of Defense
- NIH HHS
- NIAID NIH HHS
Zitieren
APA
Dussupt, V., Jensen, J. L., Thomas, P. V., Mendez-Rivera, L., Lal, K. G., Zemil McCrea, M., Swafford, I., Hernandez, J., Sankhala, R. S., Rao, M., Arora, J., Hajduczki, A., Jian, N., Rees, P. A., Showell-De Leon, I., Smith, G., Smith, L., Wasson, D., Schmid, A., …, & Krebs, S. J. (2025). First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. https://doi.org/10.1128/mbio.01036-25
Vancouver
Dussupt V, Jensen JL, Thomas PV, Mendez-Rivera L, Lal KG, Zemil McCrea M, et al. First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge. mBio. 2025. doi:10.1128/mbio.01036-25
BibTeX
@article{Dussupt2025,
author = {Dussupt, Vincent and Jensen, Jaime L and Thomas, Paul V and Mendez-Rivera, Letzibeth and Lal, Kerri G and Zemil McCrea, Michelle and Swafford, Isabella and Hernandez, Joana and Sankhala, Rajeshwer S and Rao, Mekhala and Arora, Juhi and Hajduczki, Agnes and Jian, Ningbo and Rees, Phyllis A and Showell-De Leon, Indica and Smith, Gabriel and Smith, Lauren and Wasson, Diana and Schmid, Annika and Teng, I-Ting and Zhou, Tongqing and Kwong, Peter D and Currier, Jeffrey R and Reiley, William W and Paquin-Proulx, Dominic and Polonis, Victoria R and Collins, Natalie D and Michael, Nelson L and Joyce, M Gordon and Krebs, Shelly J},
title = {First-generation N-terminal domain supersite public antibodies retain activity against Omicron-derived lineages and protect mice against Omicron BA.5 challenge},
journal = {mBio},
year = {2025},
doi = {10.1128/mbio.01036-25}
}
EUVIMED